anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Many patients who have undergone a periacetabular osteotomy (PAO) for developmental dysplasia of the hip (DDH) have had jobs preoperatively. Postoperative return to work and work productivity are important for livelihood security and the social economy. However, there is a lack of evidence on work productivity after PAOs. Therefore, this study investigated the return to work rates and influence of workload, clinical, and radiographic parameters on work productivity after a curved PAO.
MATERIALS AND METHODS: In this study, the data of 68 hip joints among 48 participants who underwent curved PAO for symptomatic DDH were analyzed. Correlations between postoperative work productivity and clinical, radiographic, and workload parameters were assessed. Work productivity was evaluated using the Work Productivity and Activity Impairment (WPAI) questionnaire. Clinical factors were assessed using the modified Harris Hip Scores (mHHS) and University of California, Los Angeles Activity scores. Preoperative and postoperative radiographic parameters were compared with postoperative work productivity. The workload was categorized using the Reichsausschuß für Arbeitszeitermittlung (REFA)-classification system.
RESULTS: Of the participants, 98% returned to work and 87.5% returned to their original jobs. Work productivity was significantly improved in all workload categories at the 1-year postoperative follow-up. Multivariate analysis demonstrated that preoperative Tönnis and REFA classification grades were significantly associated with the postoperative WPAI.
CONCLUSION: Curved PAOs can improve postoperative work productivity and return to work rates. Preoperative progression of osteoarthritis and heavy workload affect postoperative work productivity.
The invention provides dendritic-like cell/tumor cell hybridomas and pluralities of dendritic-like cell/tumor cell hybrids that confer tumor resistance in vivo. The hybrids and hybridomas are generated by the fusion of tumor cells with dendritic-like cells. For instance, immortal tumor cells from an autologous tumor cell line can be fused with autologous or HLA-matched allogeneic dendritic-like cells. Autologous tumor cell lines can be derived from primary tumors and from their metastases. Alternatively, immortal dendritic-like cells from an autologous or allogeneic HLA-matched dendritic-like cell line can be fused with autologous tumor cells. Autologous dendritic-like cell lines can be prepared from various sources such as peripheral blood and bone marrow. Dendritic-like cell/tumor cell hybridomas and pluralities of hybrids can be directly infused for active immunization of cancer patients against their residual tumor cells. The hybridomas and hybrids can also be used for the in vitro activation of autologous immune cells before their reinfusion into the patient for passive immunization against the tumor cells.
Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
Objective: To study the SUV3 gene role during the process of occurrence and advancement of hepatocellular carcinom. Methods: The The differences in SUV3 expression between hepatocellular carcinoma tissues and normal liver tissues were compared by analyzing transcriptome sequencing data from TCGA and GTEx databases. SUV3 knockdown in different hepatocellular carcinoma cells was performed using RNA interference technology. Overexpression vectors were constructed to overexpress SUV3 in different hepatocellular carcinoma cells. The SUV3 regulatory effect was studied on proliferation, migration, and invasion of hepatocellular carcinoma cells. A subcellular fraction isolation approach was used to investigate whether SUV3 knockdown resulted in the release of mitochondrial DNA into the cytoplasm. Quantitative reverse transcription PCR was applied to investigate whether SUV3 knockdown affected PD-L1 expression. The two groups were compared using a two-tailed t-test. Results: The TCGA database analysis revealed that SUV3 expression was higher in hepatocellular carcinoma tissues than in normal liver tissues, and the prognosis of patients with high SUV3 expression in hepatocellular carcinoma tissues was poor. The quantitative RT-PCR results showed that SUV3 expression was higher in hepatocellular carcinoma tissues than that in paracancerous liver tissue. The MTS assay showed that with SUV3 knockdown, the proliferation rate was significantly lower in hepatocellular carcinoma cells than that of the control hepatocellular carcinoma cells (P<0.01). The proliferation rate was significantly higher in SUV3-overexpressed hepatocellular carcinoma cells than that of control hepatocellular carcinoma cells (P<0.01). Cell scratch assay and cell migration and invasion assay showed that SUV3 knockdown inhibited the migration and invasion of hepatocellular carcinoma cells (P<0.01), while SUV3 overexpression promoted the migration and invasion of hepatocellular carcinoma cells (P<0.05). SUV3 Knockdown led to a decrease in the overall level of mtDNA (P<0.01) in accompanied by an increase in mtDNA level in the cytoplasm (P<0.01), indicating that SUV3 knockdown led to mitochondrial DNA leakage into the cytoplasm. SUV3 knockdown resulted in elevated PD-L1 expression (P<0.001), and overexpression of TREX1 in SUV3 knockdown cells decreased mtDNA levels in the cytoplasm and inhibited SUV3 knockdown, resulting in elevated PD-L1 expression, indicating that SUV3 knockdown induced PD-L1 expression by increasing cytoplasmic DNA levels. Conclusions: The SUV3 gene may play an oncogenic function in hepatocellular carcinoma cells.
The patients were treated by aneurysm clipping in our hospital in the previous nine months, and normal saline (0.9% Sodium Chloride Injection) had applied as intraoperative perfusion solution in operation of the historical control group. All of the 35 patients selected should meet the inclusion and exclusion criteria of this study.
Classifying retinal diseases is a complex problem because the early problematic areas of retinal disorders are quite small and conservative. In recent years, Transformer architectures have been successfully applied to solve various retinal related health problems. Age-related macular degeneration (AMD) and diabetic macular edema (DME), two prevalent retinal diseases, can cause partial or total blindness. Diseases therefore require an early and accurate detection. In this study, we proposed Vision Transformer (ViT), Tokens-To-Token Vision Transformer (T2T-ViT) and Mobile Vision Transformer (Mobile-ViT) algorithms to detect choroidal neovascularization (CNV), drusen, and diabetic macular edema (DME), and normal using optical coherence tomography (OCT) images. The predictive accuracies of ViT, T2T-ViT and Mobile-ViT achieved on the dataset for the classification of OCT images are 95.14%, 96.07% and 99.17% respectively. Experimental results obtained from ViT approaches showed that Mobile-ViT have superior performance with regard to classification accuracy in comparison with the others. Overall, it has been observed that ViT architectures have the capacity to classify with high accuracy in the diagnosis of retinal diseases.
Neonates age 0-18 weeks post-partum at enrollment with gestational age \> 28 weeks will have the Gravitas Feeding Tube placed using standard technique. Tube placement will be verified by the institution standard of care. Study tubes are to remain in place up to 30 days.
Bromfenac ophthalmic solution, 0.075% is supplied in white opaque low density polyethylene (LDPE) bottle closed with natural LDPE Nozzle and sealed with gray colored HDPE Cap. Tamper evidence provided by tamper evident ring. Each bottle is packed in a carton.

5 mL in a 10 mL bottle

(NDC No. 68180-434-01)

Storage: Store at 15ºC to 25ºC (59ºF to 77 ºF). After opening, bromfenac ophthalmic solution can be used until the expiration date on the bottle. Discard after treatment completion.
The participants above 20 years old who are newly diagnosed with mild to severe OSA (Apnea-hypopnea Index \>5/h), and the physician will explain the treatment programs to every subject. By their willingness to choose the therapeutic method, the participants who select the surgery interventions will be assign to TORS or TORS+OPR group. The matched controls as well as age-, sex-, and body mass index-matched OSA participants will be selected from the patients who are waiting for oral appliance, losing weight and using continuous positive airway pressure. Before surgery, 6 week and 18 week after surgery, the investiagters will compare the polysomnography data, questionnaires of sleep quality, drug-induced sleep endoscopy and computed tomography as primary outcomes. The investigators will also compare the tongue and jaw-opening muscle strength and biomarkers of oxidative stress, anti-oxidative stress, inflammatory cytokines and matrix metalloproteinases 9 as secondary outcomes. The OPR would begin at 6 week after surgery, and participants will undergo three months of the home-based oropharyngeal myofunctional therapeutic training. During the training intervention period, participants will be interviewed one time per week for adjusting the treatment intensity.
The disclosed technology relates to a platform for providing improved compliance with a customized medical care plan. A customized medical care plan is generated based on a health condition of a user. A first measurement is solicited at a first predetermined time period. The first measurement is received from a measurement device within the first predetermined time period. A compliance score is generated based on receipt of the first measurement within the first predetermined time period. An intervention can be initiated based on the generated compliance score and the first measurement.
The invention discloses a healthcare product for relieving physical fatigue and a preparation method of the healthcare product for relieving physical fatigue. The method includes: subjecting Lycium barbarum to alcohol extraction, subjecting flos chrysanthemi, rhodiola rosea and Lycium barbarum residues to water extraction, concentrating and drying to obtain dry extracts, uniformly mixing with yams, grinding to obtain mixed powder, and encapsulating to obtain the healthcare product for relieving physical fatigue. Compared with the prior art, the healthcare product for relieving physical fatigue is prepared from traditional Chinese medicinal materials, simple in prescription and reasonable in ingredient and has functions of spleen tonifying, stomach nourishing, body fluid regenerating, lung benefiting and fatigue resistance, and effective rate of the anti-fatigue function of the product is 100% approximately. The healthcare product prepared according to the method is pretty convenient for human body to absorb. According to experiments in mice, swimming exhausting time of an experimental mouse burdened with a lead sheath in weight 5% of the body weight of the mouse is evidently longer than a blank control group, and difference between the blank control group and each of a high-dose group and a middle-dose group is pretty evident. According to blood lactate measurement, the healthcare product gives play to the anti-fatigue function by means of acceleration of elimination of blood lactates.
Use of a complex nutrient medium (A) that, when used alone or in aq. medium, provides viable in vitro culture of an inoculum of human epidermal keratinocytes, for the prepn. of a topical compsn. is new. The medium ensures \-1 clonal proliferation of the cells during the first or last passage without a feeder layer of living cells. Also claimed are topical cosmetic and pharmaceutical compsns. biocompatible with the human body surface, contg. homogeneously distributed (A).
Oil-in-water compsns. are prepd. by using a generator of shock waves either without an emulsifier or in the presence of 1% surfactant such as a nonionic ethylene oxide condensate. The shock waves are provided by an appts. comprising a generator of superheated water operating continuously in a pulsating manner, the sudden decompression being regulated by a pressostat. Examples specified are in dairy foods made from milk and serum, and cheese coloured with carotene emulsion; also as a fermentation medium for producing amino acids and as a vaccine support; as in polymer emulsions and emulsion polymerisation and in exterior emulsion paints. As they do not require an emulsifier, which contributes some instability to the emulsions, they are more stable. They are stable at >60 degrees C in neutral or basic medium and in acid medium in the presence of a protective colloid.
Observation until disease progression. Long term follow-up 5 years post last patient randomized.
PROBLEM TO BE SOLVED: To obtain a composition capable of being stably stored and useful for preparing compositions for applying to a local part, by making dispersions of lipid vesicles contain acidic activators. SOLUTION: This acidic composition comprises a composition containing lipid vesicles having aqueous cores and/or a dispersion of lipid vesicles having oily cores and an acidic compound (e.g. lactic acid) in an amount of 0.1-10 wt.% based on the whole weight of the composition to adjust pH of the composition at 2.8-4.8. Lipid vesicles not containing acidic amphipathic lipids are used when a lipid membrane of the vesicles has an aqueous core and lipid vesicles not containing a not-hydrogenated soybean lecithin are also used when glycerol exists in the dispersion. The compositions are oil-in-water type dispersants and especially act as dispersants of an oil into an aqueous phase in which lipid vesicles are continued.  The composition can be used for maintaining the face and the body or for making up, and are non-therapeutically applied to wrinkles, fine wrinkles and a pimple due to an acnes.
This sample will receive health education. The participant will read chapters from the book, "Living a Healthy Life with chronic conditions," 5th edition, by K Lorig, D Laurent, V Gonzalez, D Sobel, M Minor and M Gecht-Silver, and review chapters with the unblinded study coordinator.
There have been cases of lipohypertrophy in patients treated with SOMAVERT. In a double-blind, 12-week, placebo-controlled study, there was one case (1.3%) of injection site lipohypertrophy reported in a subject receiving 10 mg/day. The subject recovered while on treatment. Among two open-label trials (with a total of 147 patients), there were two subjects, both receiving 10 mg/day, who developed lipohypertrophy. One case recovered while on treatment, and one case resulted in a discontinuation of treatment. Injection sites should be rotated daily to help prevent lipohypertrophy (different area than the last injection).
This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
Renal fibrosis is a representative pathological feature of various chronic kidney diseases, and efficient treatment is needed. Interstitial myofibroblasts are a key driver of kidney fibrosis, which is dependent on the binding of TGF-β1 to type I TGF-β receptor (TβRI) and TGF-β1-related signaling pathways. Therefore, attenuating TGF-β1 activity by competing with TGF-β1 in myofibroblasts is an ideal strategy for treating kidney fibrosis. Recently, a novel TβRI-mimicking peptide RIPΔ demonstrated a high affinity for TGF-β1. Thus, it could be speculated that RIPΔ may be used for anti-fibrosis therapy. Platelet-derived growth factor β receptor (PDGFβR) is highly expressed in fibrotic kidney. In this study, we found that target peptide Z-RIPΔ, which is RIPΔ modified with PDGFβR-specific affibody ZPDGFβR, was specifically and highly taken up by TGF-β1-activated NIH3T3 fibroblasts. Moreover, Z-RIPΔ effectively inhibited the myofibroblast proliferation, migration and fibrosis response in vitro. In vivo and ex vivo experiments showed that Z-RIPΔ specifically targeted fibrotic kidney, improved the damaged renal function, and ameliorated kidney histopathology and renal fibrosis in UUO mice. Mechanistic studies showed that Z-RIPΔ hold the stronger inhibition of the TGF-β1/Smad and TGF-β1/p38 pathways than unmodified RIPΔ in vitro and in vivo. Furthermore, systemic administration of Z-RIPΔ to UUO mice led to minimal toxicity to major organs. Taken together, RIPΔ modified with ZPDGFβR increased its therapeutic efficacy and reduced its systemic toxicity, making it a potential candidate for targeted therapy for kidney fibrosis.
Vascular diseases constitute a significant contributor to worldwide mortality rates, placing a substantial strain on healthcare systems and socio-economic aspects. They are closely associated with inflammatory responses, as sustained inflammation could impact endothelial function, the release of inflammatory mediators, and platelet activation, thus accelerating the progression of vascular diseases. Consequently, directing therapeutic efforts towards mitigating inflammation represents a crucial approach in the management of vascular diseases. Traditional anti-inflammatory medications may have extensive effects on multiple tissues and organs when absorbed through the bloodstream. Conversely, treatments targeting inflammatory vascular diseases, such as monoclonal antibodies, drug-eluting stents, and nano-drugs, can achieve more precise effects, including precise intervention, minimal non-specific effects, and prolonged efficacy. In addition, personalized therapy is an important development trend in targeted therapy for inflammatory vascular diseases. Leveraging advanced simulation algorithms and clinical trial data, treatment strategies are gradually being personalized based on patients' genetic, biomarker, and clinical profiles. It is expected that the application of precision medicine in the field of vascular diseases will have a broader future. In conclusion, targeting therapies offer enhanced safety and efficacy compared to conventional medications; investigating novel targeting therapies and promoting clinical transformation may be a promising direction in improving the prognosis of patients with inflammatory vascular diseases. This article reviews the pathogenesis of inflammatory vascular diseases and presents a comprehensive overview of the potential for targeted therapies in managing this condition.
PURPOSE:To obtain an agent for proliferating and strengthening antibody- producing cell and useful as a remedy for various immunodeficiency diseases caused by the lowering of macrophage function, by culturing a macrophage and using the obtained supernatant liquid of the cultured product as an active component. CONSTITUTION:Floating cell in abdominal cavity or spleen cell, etc., of mammal such as mouse is cultured in an animal cell cultivation medium containing serum of mammal at 36-38 deg.C in a carbon dioxide gas culture vessel for 20-40min and the cultivation process is repeated several times to obtain a macrophage. The supernatant liquid of the cultured liquid is separated e.g. by centrifugal separation and used as an active component, which is converted into a medical preparation to obtain the titled agent. The dose of the active component is 0.1-100mug, preferably 1-10mug per 1kg of body weight for adult. It can be administered in the form of injection, solution, ointment, suppository, etc.
FIELD: medicine; medical technology.SUBSTANCE: inventions group relates to medicine and medical technology, namely to cardiovascular surgery. In case of hypothermia at 26°C and stopping the systemic IC, the damaged aortic arch is dissected. The mouth of the left subclavian artery is cut off and clamped. A distal anastomosis is formed with the descending part of the thoracic aorta by installing the distal part of the vascular prosthesis of the aortic arch inside the descending part of the thoracic aorta. After that, the "skirt" -cuff is sewn to the descending part of the thoracic aorta, then the systemic IR is restored through the additional branch of the aortic arch prosthesis. A clamp is applied to the proximal part of the arch prosthesis. An anastomosis is formed between the third branch of the trifurcation prosthesis and the left subclavian artery. An intervascular anastomosis is formed between the prostheses of the ascending part and the aortic arch. The main branch of the aortic arch prosthesis is clamped and, after the prevention of air embolism, cardiac activity is restored. On the beating heart, an end-to-end intervascular anastomosis is formed between the main jaws of the trifurcation prosthesis and the main jaws of the aortic arch prosthesis. After stabilization of hemodynamics, IC is completed. The specified method is implemented by means of a synthetic vascular prosthesis of the aortic arch, which includes a main branch, an additional perfusion branch and a "skirt" -cuff. The specified prosthesis is made by fixing a woven knitted cuff in the form of a flat ring to a linear vascular prosthesis of the aortic arch. Then an additional branch of the aortic arch prosthesis is formed by suturing a vascular synthetic prosthesis with a diameter of 8 mm to a linear vascular aortic arch prosthesis with a "skirt" -cuff. After that, the main branch of the aortic arch prosthesis is formed, for which the linear vascular prosthesis is sutured at an angle to the linear vascular aortic arch prosthesis with a "skirt" cuff and an additional branch. Then a multilayer coating is applied to the surface of the product, where the first layer is a layer of protein, the second is a layer of anticoagulant - heparin, the third is a layer of a biodegradable coating based on gelatin and drugs with antimicrobial and antiplatelet action, while glutaraldehyde is used as a crosslinking agent, and plasticizer - glycerin, then the resulting prosthesis is sterilized with ethylene oxide at 37°C.EFFECT: inventions group makes it possible to preserve cerebral, cardiac and visceral blood flow at the stage of end-to-end intervascular anastomosis between the main branch of the aortic arch prosthesis and trifurcation prosthesis on the beating heart in patients with dissection of the ascending part and the aortic arch.7 cl, 3 dwg, 1 ex
NOT FOR INJECTION INTO THE EYE. This product should never be directly introduced into the anterior chamber of the eye or injected subconjunctivally.

Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known.

The manifestations of sensitization to topical antibiotics are usually itching, reddening and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication.

Applications of products containing these ingredients should be avoided for the patient thereafter. (See PRECAUTIONS, General)